
Jan Skrha

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1443222/publications.pdf Version: 2024-02-01



ΙλΝ ΟΚΟΗΛ

#	Article	IF	CITATIONS
1	Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, The, 2005, 366, 1279-1289.	13.7	3,840
2	Insulin Resistance and Hyperinsulinemia. Diabetes Care, 2008, 31, S262-S268.	8.6	611
3	Oral Sulodexide Reduces Albuminuria in Microalbuminuric and Macroalbuminuric Type 1 and Type 2 Diabetic Patients. Journal of the American Society of Nephrology: JASN, 2002, 13, 1615-1625.	6.1	182
4	Advanced glycoxidation end products in chronic diseases—clinical chemistry and genetic background. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 579, 37-46.	1.0	167
5	Gene polymorphisms of superoxide dismutases and catalase in diabetes mellitus. BMC Medical Genetics, 2008, 9, 30.	2.1	127
6	Insulin Sensitivity in Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2942-2945.	3.6	115
7	Glucose variability, HbA1c and microvascular complications. Reviews in Endocrine and Metabolic Disorders, 2016, 17, 103-110.	5.7	105
8	Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technology and Therapeutics, 2016, 18, 532-538.	4.4	100
9	Glycemic Variability Is Higher in Type 1 Diabetes Patients with Microvascular Complications Irrespective of Glycemic Control. Diabetes Technology and Therapeutics, 2014, 16, 198-203.	4.4	96
10	Comparison of the Insulin Action Parameters from Hyperinsulinemic Clamps with Homeostasis Model Assessment and QUICKI Indexes in Subjects with Different Endocrine Disorders. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 135-141.	3.6	93
11	Angiopoietin-like protein 3 and 4 in obesity, type 2 diabetes mellitus, and malnutrition: the effect of weight reduction and realimentation. Nutrition and Diabetes, 2018, 8, 21.	3.2	52
12	Comparison of laser-Doppler flowmetry with biochemical indicators of endothelial dysfunction related to early microangiopathy in Type 1 diabetic patients. Journal of Diabetes and Its Complications, 2001, 15, 234-240.	2.3	41
13	Oxidative stress and endothelium influenced by metformin in type 2 diabetes mellitus. European Journal of Clinical Pharmacology, 2007, 63, 1107-1114.	1.9	37
14	Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes. European Journal of Pharmacology, 2004, 493, 183-189.	3.5	35
15	New methodology of influential point detection in regression model building for the prediction of metabolic clearance rate of glucose. Clinical Chemistry and Laboratory Medicine, 2004, 42, 311-22.	2.3	33
16	Prevalence and Risk Factors of Osteoporosis in Postmenopausal Women with Type 2 Diabetes Mellitus. Central European Journal of Public Health, 2017, 25, 3-10.	1.1	31
17	Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D). Journal of Diabetes and Its Complications, 2005, 19, 80-87.	2.3	28
18	Increased tissue and circulating levels of dipeptidyl peptidase-IV enzymatic activity in patients with pancreatic ductal adenocarcinoma. Pancreatology, 2016, 16, 829-838.	1.1	28

Jan Skrha

#	Article	IF	CITATIONS
19	Plasma Malondialdehyde and Obesity: Is there a Relationship?. Clinical Chemistry and Laboratory Medicine, 1999, 37, 1129-30.	2.3	26
20	Serum α-tocopherol and ascorbic acid concentrations in Type 1 and Type 2 diabetic patients with and without angiopathy. Clinica Chimica Acta, 2003, 329, 103-108.	1.1	22
21	2,3,7,8-TCDD exposure, endothelial dysfunction and impaired microvascular reactivity. Human and Experimental Toxicology, 2007, 26, 705-713.	2.2	22
22	Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss. Pancreatology, 2017, 17, 89-94.	1.1	20
23	Glycosaminoglycan therapy for long-term diabetic complications?. Diabetologia, 1998, 41, 975-979.	6.3	16
24	Relationship of serum N-acetyl-β-glucosaminidase activity to oxidative stress in diabetes mellitus. Clinica Chimica Acta, 1999, 282, 167-174.	1.1	16
25	Serum microRNA-196 and microRNA-200 in pancreatic ductal adenocarcinoma of patients with diabetes mellitus. Pancreatology, 2016, 16, 839-843.	1.1	15
26	Early detection of pancreatic cancer. European Journal of Gastroenterology and Hepatology, 2016, 28, e33-e43.	1.6	14
27	Early detection of sporadic pancreatic cancer: time for change. European Journal of Gastroenterology and Hepatology, 2017, 29, 885-891.	1.6	13
28	Early changes of serum N-acetyl-β-glucosaminidase, tissue plasminogen activator and erythrocyte Superoxide dismutase in relation to retinopathy in type 1 diabetes mellitus. Clinica Chimica Acta, 1994, 229, 5-14.	1.1	12
29	Evidence for the presence of a free N-terminal fibronectin 30-kDa domain in human plasma by quantitative determination with an indirect immunosorbent assay. Analytical Biochemistry, 1988, 173, 228-234.	2.4	11
30	Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. American Heart Journal, 2002, 144, G1-G8.	2.7	11
31	Induction of the mitochondrial permeability transition (MPT) by micromolar iron: Liberation of calcium is more important than NAD(P)H oxidation. Biochimica Et Biophysica Acta - Bioenergetics, 2012, 1817, 1537-1549.	1.0	10
32	Precursors of pancreatic cancer. European Journal of Gastroenterology and Hepatology, 2017, 29, e13-e18.	1.6	10
33	Diabetes, Cardiovascular Disorders and 2,3,7,8â€Tetrachlorodibenzoâ€ <i>pâ€</i> Dioxin Body Burden in Czech Patients 50ÂYears After the Intoxication. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 356-359.	2.5	10
34	Can the atherosclerosis prevention targets be achieved in type 2 diabetes?. Diabetes Research and Clinical Practice, 2005, 68, S48-S51.	2.8	8
35	Early pancreatic carcinogenesis – risk factors, early symptoms, and the impact of antidiabetic drugs. European Journal of Gastroenterology and Hepatology, 2016, 28, e19-e25.	1.6	7
36	Serum lipase, isoamylase and pancreatic function test (PFT) in juvenile-onset insulin-dependent diabetes mellitus. Acta Diabetologica Latina, 1983, 20, 357-361.	0.2	6

Jan Skrha

#	Article	IF	CITATIONS
37	Chapter 8 Effect of Caloric Restriction on Oxidative Markers. Advances in Clinical Chemistry, 2009, , 223-247.	3.7	6
38	Diabetes mellitus—a global pandemicKeynote lecture presented at the Wonca conference in Prague in June 2013. European Journal of General Practice, 2014, 20, 65-68.	2.0	6
39	Diabetes, Lipids, and CV Risk. Current Atherosclerosis Reports, 2021, 23, 8.	4.8	6
40	Diabetes and vascular disease: From pathogenesis to treatment. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2007, 1, 61-69.	3.6	5
41	Acute Hyperglycemia Does Not Impair Microvascular Reactivity and Endothelial Function during Hyperinsulinemic Isoglycemic and Hyperglycemic Clamp in Type 1 Diabetic Patients. Experimental Diabetes Research, 2012, 2012, 1-8.	3.8	4
42	Serum isoamylase activities during infusions of glucose and amino acids. European Journal of Clinical Investigation, 1986, 16, 35-38.	3.4	3
43	Serum and urinary amylase isoenzymes in carcinoma of the prostate. Clinica Chimica Acta, 1982, 121, 11-14.	1.1	2
44	Postprandial microvascular reactivity is significantly modified by endogenous insulin in recently diagnosed Type 2 diabetic patients. Diabetes Research and Clinical Practice, 2018, 139, 300-307.	2.8	2
45	Lipid peroxidation and impaired vascular function in patients with type 1 diabetes mellitus. Monatshefte Für Chemie, 2019, 150, 525-529.	1.8	2
46	Sporadic Pancreatic Cancer: Glucose Homeostasis and Pancreatogenic Type 3 Diabetes. , 0, , .		1
47	Prediction of insulin sensitivity in non-obese women with polycystic ovary syndrome. Fertility and Sterility, 2002, 78, S279.	1.0	0